Fear over NICE guidance on prostate cancer drug

January 28, 2014 2:19 pm

It’s been claimed that thousands of men with advanced prostate cancer could be denied a new drug following guidance from NICE. NICE initially recommended for NHS funding last October but have reversed this decision. NICE have justified the decision claiming there is a lack of evidence.  Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months. However, it will be banned for patients in England previously treated with abiraterone, another new drug currently used in advanced cases.

The pharmaletter.

January 28, 2014 2:19 pm

*/?>

If you would like to receive information and analysis on policy developments across our specialist sectors, please complete the following, indicating what sectors you would like to receive information on:







Contact us

We would be delighted to hear from you. If you would like to get in touch with us, please contact us on 020 7463 0690 or use the form below.

We look forward to hearing from you.

For media enquiries, please contact Mayar Raouf on 020 7463 0698 / 0750 232 7092, or email Mayar.Raouf@whitehouseconsulting.co.uk.

Contact us via email

Sign up for the latest news

  • * Denotes required fields
  • This field is for validation purposes and should be left unchanged.

Contact us

  • * Denotes Required fields
  • This field is for validation purposes and should be left unchanged.